Skip to content

CRISPR Uricase

Restoring functional UOX in human liver cells attacks urate production upstream of crystallization. The active evidence is an in-vitro proof of concept; no cited study establishes safe, durable urate control in an animal or human through this approach.

What has been demonstrated

Balico and Gaucher inserted an ancestral uricase construct into the genome of human hepatocyte monolayers and spheroids. Expression reduced intracellular urate and prevented the fructose-associated increase in triglyceride production in those culture systems (Scientific Reports 2025, PMID 40681749). In Vitro.

The result establishes that the reconstructed enzyme can function in the tested human-cell models. It does not establish in-vivo delivery, the fraction of hepatocytes that must be modified, durability, a safe serum-urate set point, off-target editing risk, vector safety, peroxide handling, clinical efficacy, or clinical availability.

The earlier ancestral-reconstruction program supplies protein-level evolutionary and structural evidence, including reconstructed uricases tested in biochemical, cell, and rodent pharmacokinetic settings (PNAS 2014, PMID 24550457). Those data inform candidate selection but do not substitute for an in-vivo edited-liver study. In Vitro + Animal Model, with Mechanistic Extrapolation to gene restoration.

Translational questions

A decision-grade program must resolve:

  1. Delivery and editing: which liver-directed system reaches enough hepatocytes with acceptable off-target, inflammatory, and hepatic effects?
  2. Expression control: is UOX activity durable and regulatable, and can it avoid overshooting the intended urate range?
  3. Reaction safety: how are UOX-derived hydrogen peroxide and the loss of urate's antioxidant contribution handled in vivo?
  4. Metabolic scope: do the intracellular urate and triglyceride findings reproduce in an intact organism without an adverse metabolic tradeoff?
  5. Disease outcomes: does the intervention lower circulating urate and crystal burden, and what happens to flare risk while deposits mobilize?

The last question is a trial-design concern, not a treatment protocol. The direction, magnitude, and timing of any flare effect after hepatic UOX restoration are unmeasured. Mechanistic Extrapolation.

Falsification sequence

  1. Reproduce construct expression, localization, urate turnover, peroxide, and cell-state readouts with inactive-UOX and edit-only controls.
  2. Demonstrate liver delivery, editing distribution, circulating urate effects, peroxide handling, and short-term safety in an appropriate in-vivo model.
  3. Test durability, dose control, off-target changes, immune response, metabolic effects, and crystal-burden outcomes before any clinical claim.

Failure to control expression or reaction safety redirects the approach toward regulatable or transient expression; failure to lower circulating urate at an acceptable safety margin kills the therapeutic hypothesis in that configuration.

Relationship to other Open Enzyme tracks

Hepatic gene restoration is an independent research track. It is not contingent on engineered yeast or koji succeeding, and those constructs are not validated bridge therapies while gene restoration develops. Each route advances only through its own evidence and safety gates.